EUVIMEDEUVIMED entdecken
Open Access

The Expression and Prognostic Significance of ICOS in NSCLC Integrated Pan-Cancer and Multi-Omics Analyses

Mengting Chen, Xiaotian Yan, Bo Hong, Yufei Xiao, Yun Qian

International Journal of Medical Sciences · 2024

DOI: 10.7150/ijms.93262 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Medical Sciences, 2024. Verfasst von Mengting Chen und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Laboratory, Stomatology Hospital, School of Stomatology, Zhejiang University School of Medicine, Zhejiang Provincial Clinical …. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Inducible co-stimulator (ICOS) shows great potential in the regulation of innate and adaptive immunity. However, previous studies of ICOS have often been limited to one or two levels.

Methods

Using the data from the online database, the immunohistochemistry, and enzyme-linked immunosorbent assays, we investigated the role of ICOS / PD-L1 on patients with NSCLC at the mRNA, protein, and serum levels.

Results

Our data revealed that unlike most solid tumors, the mRNA expression of ICOS was down-regulated in NSCLC. In addition, our data also showed that mRNA expression levels in ICOS are negatively associated with poor clinicopathologic grading but positively associated with better prognostic outcomes and higher Tregs infiltration level. Immunohistochemistry showed that ICOS correlated negatively with the T stage; while PD-L1 levels correlated positively with the N stage and FOXP3 levels. Serological biomarker analysis showed that patients with NSCLC had lower sICOS levels, which increased significantly post-surgery, and combined sICOS and sPD-L1 diagnosis improved efficacy and accuracy of disease diagnosis.

Conclusion

Our findings support that ICOS suggests lower pathological staging and better prognosis. ICOS is a potential diagnostic and prognostic biomarker for NSCLC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsHumansB7-H1 AntigenPrognosisMultiomicsRNA, MessengerBiomarkersInducible T-Cell Co-Stimulator Protein

Stichwörter der Autor:innen

ICOSNSCLCPD-L1immune infiltrationimmunohistochemistrysoluble ICOS/PD-L1

Substanzen

B7-H1 AntigenRNA, MessengerBiomarkersICOS protein, humanInducible T-Cell Co-Stimulator Protein

Autor:innen und Institutionen

  • Department of Clinical Laboratory, Stomatology Hospital, School of Stomatology, Zhejiang University School of Medicine, Zhejiang Provincial Clinical Research Center for Oral Diseases, Key Laboratory of Oral Biomedical R…
  • Department of Pathology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China.
  • Department of Clinical Laboratory, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China.

Zitieren

APA

Chen, M., Yan, X., Hong, B., Xiao, Y., & Qian, Y. (2024). The Expression and Prognostic Significance of ICOS in NSCLC Integrated Pan-Cancer and Multi-Omics Analyses. International Journal of Medical Sciences. https://doi.org/10.7150/ijms.93262

Vancouver

Chen M, Yan X, Hong B, Xiao Y, Qian Y. The Expression and Prognostic Significance of ICOS in NSCLC Integrated Pan-Cancer and Multi-Omics Analyses. International Journal of Medical Sciences. 2024. doi:10.7150/ijms.93262

BibTeX
@article{Chen2024,
  author = {Chen, Mengting and Yan, Xiaotian and Hong, Bo and Xiao, Yufei and Qian, Yun},
  title = {The Expression and Prognostic Significance of ICOS in NSCLC Integrated Pan-Cancer and Multi-Omics Analyses},
  journal = {International Journal of Medical Sciences},
  year = {2024},
  doi = {10.7150/ijms.93262}
}
Kostenlos starten →